Our focus is expanding affordable access to NARCAN® (naloxone HCl) Nasal Spray - the leading
community use naloxone - and progressing our pipeline of opioid overdose and addiction treatments.


Adapt Pharma facilitates NARCAN® (naloxone hydrochloride) Nasal Spray access to state and local public entities

January 14, 2016

U.S. Communities Purchasing Alliance Members Gain Access to Opioid Overdose Treatment at Discounted Public Interest Price

Dublin, Ireland – January 14, 2016 – In support of White House efforts to address the opioid overdose epidemic and today’s community forum in Knoxville, Tennessee, Adapt Pharma, Limited (“Adapt Pharma”) today announced that it has reached an agreement to facilitate the purchase of NARCAN Nasal Spray by offering its discounted Public Interest Price to 62,000 agencies in state and local government and the non-profit sector.

Adapt Pharma, in partnership with the National Association of Counties, National Governors Association, National League of Cities and United States Conference of Mayors, will offer NARCAN Nasal Spray at a discounted Public Interest Price of $37.50 per dose ($75 for a 2 pack carton) through the U.S. Communities Purchasing Alliance andPremier, Inc. To learn more click here or call 844-4-NARCAN.

NARCAN Nasal Spray is the only FDA approved, ready-to-use, nasal spray version of naloxone hydrochloride, indicated for the emergency treatment of opioid overdose. It is not a substitute for emergency medical care. See below for indication and important safety information.

“This broad partnership provides state and local government and non-profit entities access to NARCAN Nasal Spray, the only FDA approved, needle-free, ready-to-use naloxone nasal spray, at a transparent discounted price,” said Seamus Mulligan, Chairman and CEO of Adapt Pharma. “With this partnership, we are confident NARCAN Nasal Spray can play a critical role in supporting these entities’ efforts to implement scaled-up naloxone access and distribution policies in response to the growing opioid overdose crisis in communities across the nation.”

“U.S. Communities, along with our partners, are proud to have joined forces with Adapt Pharma to help fight this epidemic and to facilitate public agencies’ access to this potentially lifesaving medication,” said Chris Robb, General Manager of U.S. Communities.

This partnership comes as deaths from opioid-based prescription painkillers and heroin have reached epidemic proportions in the U.S., surging to over 29,000 in 2014, according to figures released in December 2015 by the Centers for Disease Control and Prevention.

Adapt Pharma’s discounted Public Interest Price is available to Qualifying Group Purchasers, such as law enforcement, fire fighters, first responders, departments of health, local school districts, colleges and universities, and community-based organizations. Click here for further details or call 844-4-NARCAN.


NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.


Important Safety Information

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

Adverse Reactions: The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

To report SUSPECTED ADVERSE REACTIONS, contact ADAPT Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See Instructions for Use and full prescribing information in the use of this product, available here: https://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf .

Additional information, including full prescribing information for NARCAN® Nasal Spray, and important safety information and instructions for use, is also available at www.NARCAN.com.